The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

Launched by CHINESE SLE TREATMENT AND RESEARCH GROUP · Jun 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called deucravacitinib to see how well it works and how safe it is for adults with Takayasu Arteritis (TAK), a rare inflammatory disease that affects the blood vessels. The trial will last for 24 weeks and compare the effects of deucravacitinib to a well-known treatment called TNF inhibitors, which are often used for patients who have not responded well to other therapies.

To participate, adults aged 18 or older must have active TAK that hasn't improved with previous treatments and meet specific health criteria. Participants will need to provide informed consent, meaning they understand the study's purpose and agree to take part. Women who can become pregnant must be careful about pregnancy during the study. Overall, if eligible, participants can expect to receive either the new treatment or the standard one while being closely monitored for safety and effectiveness. This trial is not yet recruiting, so interested individuals will need to wait for more information on when it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Participants are eligible to be included in the study only if all of the following criteria apply:
• • 1. Signed Written Informed Consent
• • 1. Participants fully understand the purpose, nature, method, and possible adverse reactions of the study, willing to consent to the trial and follow study protocol and sign informed consent.
• • 2. Participants must have signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. This ICF must be obtained before performing any protocol related procedures that are not part of normal patient care.
• • 2. Type of Participant and Target Disease Characteristics
• • 1. Adult patients (aged 18 or older) fulfilling the 2022 ACR/EULAR classification criteria for TAK.
• • 2. Persistence of active disease or relapse despite treatment with GCs combined with a conventional synthetic or biologics immunosuppressive agent other than TNFi.
• • 3. Active vasculitis by reader interpretation of FDG-PET at enrollment (by the same reader).
• • 3. Reproductive Status The investigator or designee shall counsel women of childbearing potential (WOCBP) and male participants who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy.
• • WOCBP must have a negative highly sensitive specify: urine or serum as required by local regulations pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study intervention.
• A female is eligible to participate if she is not pregnant or breastfeeding and at least 1 of the following conditions applies:
• • Is not a WOCBP OR Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \< 1% per year) during the intervention period and for at least 5 half-lives after product administration and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.
• • WOCBP and male participants who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception.
• Exclusion Criteria:
• * Participants are excluded from the study if any of the following criteria apply:
• • 1. Medical Conditions
• • 1. Severe disease from TAK for which urgent treatment with interventional procedures or bypass surgery is considered necessary
• • 2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia
• • 3. Active hepatitis B or C virus infection, active tuberculosis infection
• • 4. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)
• • 2. Physical and Laboratory Test Findings
• • 1. Serum liver enzyme tests 3 times higher than the upper limits of normal range
• • 2. Estimated glomerular filtration rate ≤ 30 ml/minute
• • 3. Other Exclusion Criteria
• • 1. Females who are pregnant
• • 2. Ever treated with TNFi (including adalimumab) and discontinued due to inadequate response or intolerance.
• • 3. Any other sound medical, psychiatric, and/or social reason as determined by the investigator